La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Harvard Bioscience Dividende

Dividende contrôle des critères 0/6

Harvard Bioscience n'a pas d'antécédents de versement de dividendes.

Informations clés

n/a

Rendement du dividende

n/a

Ratio de distribution

Rendement moyen de l'industrie	0.3%
Prochaine date de paiement du dividende	n/a
Date ex-dividende	n/a
Dividende par action	n/a
Résultat par action	-US$0.24
Prévisions de rendement du dividende à 3 ans	n/a

Mises à jour récentes des dividendes

Pas de mise à jour

Recent updates

Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt

Aug 07

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full Story

Jul 15

Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely

Dec 22

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price

Sep 23

Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Aug 10

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued

Apr 26

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt

Apr 11

Harvard Bioscience GAAP EPS of $0.05 beats by $0.06, revenue of $29.2M misses by $1.2M

Aug 04

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 25% Undervalued

May 04

These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively

Apr 19

Analysts Are Optimistic We'll See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO)

Apr 04

Have Insiders Sold Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Recently?

Mar 20

What Kind Of Shareholders Hold The Majority In Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares?

Mar 07

Harvard Bioscience (NASDAQ:HBIO) Shareholders Have Enjoyed A 92% Share Price Gain

Feb 17

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 35% Undervalued

Feb 02

Have Insiders Been Buying Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares This Year?

Jan 15

Harvard Bioscience: Wait For The Green Shoots Of Improvement

Jan 12

When Will Harvard Bioscience, Inc. (NASDAQ:HBIO) Become Profitable?

Dec 28

Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?

Dec 11

Stabilité et croissance des paiements

Récupération des données sur les dividendes

Dividende stable: Données insuffisantes pour déterminer si les dividendes par action de HBIO ont été stables dans le passé.

Dividende croissant: Données insuffisantes pour déterminer si les paiements de dividendes de HBIO ont augmenté.

Rendement des dividendes par rapport au marché

Harvard Bioscience Rendement des dividendes par rapport au marché

Comment le rendement du dividende de HBIO se compare-t-il à celui du marché ?
Segment	Rendement du dividende
Entreprise (HBIO)	n/a
25% du marché (US)	1.4%
25% du marché (US)	4.3%
Moyenne du secteur (Life Sciences)	0.3%
Prévisions des analystes dans 3 ans (HBIO)	n/a

Dividende notable: Impossible d'évaluer le rendement des dividendes de HBIO par rapport aux 25 % les moins bien payés par les actionnaires, car la société n'a signalé aucun versement récent.

Dividende élevé: Impossible d'évaluer le rendement des dividendes de HBIO par rapport aux 25 % des principaux payeurs de dividendes, car la société n'a signalé aucun versement récent.

Bénéfice distribué aux actionnaires

Couverture des revenus: Données insuffisantes pour calculer le ratio de distribution de HBIO afin de déterminer si ses paiements de dividendes sont couverts par les bénéfices.

Paiement en espèces aux actionnaires

Couverture des flux de trésorerie: Impossible de calculer la durabilité des dividendes car HBIO n'a signalé aucun versement.

Harvard Bioscience Dividende

Dividende contrôle des critères 0/6

Informations clés

Mises à jour récentes des dividendes

Recent updates

Harvard Bioscience, Inc. Provides Revenue Guidance for the Year 2024

Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt

Harvard Bioscience, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full Story

Harvard Bioscience, Inc. Provides Earnings Guidance for the Full Year 2024

Harvard Bioscience, Inc. to Report Q1, 2024 Results on May 07, 2024

Harvard Bioscience, Inc. Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth

Harvard Bioscience, Inc., Annual General Meeting, May 14, 2024

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS misses analyst expectations

Harvard Bioscience, Inc. Provides Revenue Guidance for the Full Year 2024

Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications At Society of Toxicology Meeting

Harvard Bioscience, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Harvard Bioscience, Inc. Provides Revenue Guidance for the Year 2023

Harvard Bioscience, Inc. to Showcase Latest Innovations in Preclinical and Organoid Research At Society for Neuroscience Conference

Harvard Bioscience, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price

President recently bought US$110k worth of stock

Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

New minor risk - Shareholder dilution

Harvard Bioscience, Inc. Provides Earnings Guidance for Full Year 2023

Now 22% undervalued after recent price drop

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Harvard Bioscience, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Now 20% undervalued

Harvard Bioscience, Inc. Appoints Jennifer Cote as Chief Financial Officer

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt

President recently bought US$105k worth of stock

Forecast breakeven date moved forward to 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Harvard Bioscience, Inc. Announces CFO Changes

President recently bought US$75k worth of stock

Insufficient new directors

Third quarter 2022 earnings released: US$0.082 loss per share (vs US$0.004 loss in 3Q 2021)

Harvard Bioscience, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Insufficient new directors

Insufficient new directors

Lead Independent Director recently bought US$83k worth of stock

President recently bought US$128k worth of stock

Forecast breakeven date pushed back to 2023

Price target decreased to US$8.50

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Harvard Bioscience GAAP EPS of $0.05 beats by $0.06, revenue of $29.2M misses by $1.2M

Harvard Bioscience, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Harvard Bioscience, Inc.(NasdaqGM:HBIO) dropped from Russell 2000 Dynamic Index

President recently bought US$111k worth of stock

Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt

President recently bought US$147k worth of stock

Forecast breakeven date pushed back to 2023

First quarter 2022 earnings released: US$0.17 loss per share (vs US$0.017 loss in 1Q 2021)

Harvard Bioscience, Inc. Introduces Smartstudy™ First of Kind, Next Generation Inhalation System Capability Improves Precision and Drives Growth

Harvard Bioscience, Inc. to Report Q1, 2022 Results on May 04, 2022

Harvard Bioscience, Inc., Annual General Meeting, May 17, 2022

Harvard Bioscience - Dressed Up And Waiting For A Suitor

Full year 2021 earnings: EPS misses analyst expectations

Harvard Bioscience, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly

Harvard Bioscience, Inc. Announces Executive Changes

Forecast breakeven date pushed back to 2022

Third quarter 2021 earnings released: US$0.004 loss per share (vs US$0.028 loss in 3Q 2020)

Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?

Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?

President recently sold US$386k worth of stock

Second quarter 2021 earnings released: US$0.01 loss per share (vs US$0.041 loss in 2Q 2020)

Price target increased to US$9.67

Harvard Bioscience, Inc. Files A Motion to Vacate the Suffolk Superior Court’S Order Allowing Plaintiff’S Motion for Sanctions

Independent Director has left the company

President notifies of intention to sell stock

Price target increased to US$9.00

Harvard Bioscience, Inc. Provides Financial Guidance for 2021

First quarter 2021 earnings released: US$0.017 loss per share (vs US$0.12 loss in 1Q 2020)

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 25% Undervalued